Creative Planning Acquires 14,010 Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL)

Creative Planning boosted its holdings in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) by 54.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 39,871 shares of the biotechnology company’s stock after purchasing an additional 14,010 shares during the quarter. Creative Planning’s holdings in Anavex Life Sciences were worth $226,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. SG Americas Securities LLC bought a new stake in shares of Anavex Life Sciences in the second quarter valued at approximately $57,000. Fiduciary Alliance LLC grew its position in Anavex Life Sciences by 45.2% in the 2nd quarter. Fiduciary Alliance LLC now owns 19,275 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 6,000 shares during the last quarter. EntryPoint Capital LLC increased its holdings in shares of Anavex Life Sciences by 371.1% during the 1st quarter. EntryPoint Capital LLC now owns 20,007 shares of the biotechnology company’s stock worth $102,000 after purchasing an additional 15,760 shares during the period. The Manufacturers Life Insurance Company raised its position in shares of Anavex Life Sciences by 8.5% during the second quarter. The Manufacturers Life Insurance Company now owns 30,510 shares of the biotechnology company’s stock valued at $129,000 after buying an additional 2,401 shares during the last quarter. Finally, Marshall Wace LLP bought a new stake in shares of Anavex Life Sciences in the second quarter valued at about $166,000. Institutional investors and hedge funds own 31.55% of the company’s stock.

Anavex Life Sciences Stock Performance

Shares of Anavex Life Sciences stock opened at $9.24 on Monday. The firm has a market cap of $783.55 million, a P/E ratio of -18.48 and a beta of 0.60. The firm’s 50-day simple moving average is $5.77 and its 200-day simple moving average is $5.21. Anavex Life Sciences Corp. has a twelve month low of $3.25 and a twelve month high of $10.45.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on AVXL. HC Wainwright restated a “buy” rating and set a $40.00 price target on shares of Anavex Life Sciences in a research note on Monday, November 4th. EF Hutton Acquisition Co. I upgraded Anavex Life Sciences to a “strong-buy” rating in a research note on Monday, July 22nd.

Anavex Life Sciences Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.